Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Drug: Ixazomib Citrate;   Drug: Pevonedistat Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials